论文部分内容阅读
１１２例女性乳腺癌病人手术切除１８４０枚淋巴结，常规病理检查无癌转移。现用连续切片，单克隆抗细胞角蛋白（ＡＥ１／ＡＥ３）、抗上皮细胞膜（ＥＭＡ）抗体及多克隆抗角蛋白抗体对肿瘤组织及所有淋巴结按ＬＳＡＢ法进行免疫染色。几种抗体均对肿瘤组织、淋巴结内微小癌灶及单个癌细胞呈现免疫染色阳性反应，尤以抗ＥＭＡ抗体反应最强。结果查出２７．７％（３１／１１２）病例及２．２７％（５０／１８４０）淋巴结内存在隐匿性微小癌转移。其中６１例病人经７年随访，显示有隐匿性微小癌转移病人肿瘤复发、远处扩散转移均较无癌转移病人高，而且术后时间短。作者对隐匿性微小癌的淋巴结内转移及其病理生物学与临床意义进行了讨论。
112 women with breast cancer underwent surgical resection of 1840 lymph nodes, and routine pathological examination showed no cancer metastasis. Serial sections, monoclonal anti-cytokeratin (AE1/AE3), anti-epithelial cell membrane (EMA) antibodies, and polyclonal anti-keratin antibodies were used to immunostain tumor tissues and all lymph nodes by the LSAB method. Several antibodies showed positive immunostaining reactions to tumor tissue, small lesions in lymph nodes, and individual cancer cells, with the strongest response to anti-EMA antibodies. The results showed that there were occult microcarcinoma metastases in 27.7% (31/112) cases and 2.27% (50/1840) lymph nodes. Of these 61 patients, after 7 years of follow-up, patients with occult microcarcinoma metastases showed higher tumor recurrence and distant metastasis than those without metastasis, and the postoperative time was short. The authors discuss the lymph node metastasis of occult microcarcinoma, its pathological biology and clinical significance.